Purple Biotech (PPBT) Profit After Tax (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Profit After Tax data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 67.05% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $27.8 million, a 311.98% increase from a year earlier, with the FY2025 full-year figure at -$26.5 million, down 263.95% from the prior year.
• Profit After Tax for Q1 2026 stood at $2.2 million, down from $23.2 million in the prior quarter.
• Over the last five years, Profit After Tax for PPBT reached as high as $23.2 million in Q4 2025 and fell as low as -$6.0 million in Q4 2022.
• Historically, Profit After Tax has averaged $3.4 million across 5 years, with a median of $3.3 million in 2024.
• Across the five-year window, Profit After Tax plunged 178.0% in 2022 and surged 3580.92% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$6.0 million in 2022, then grew by 19.59% to -$4.9 million in 2023, then soared by 112.95% to $629000.0 in 2024, then jumped by 3580.92% to $23.2 million in 2025, then sank by 90.5% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were $2.2 million in Q1 2026, $23.2 million in Q4 2025, and $1.2 million in Q3 2025.